Evaluation of an Alternative Ruxolitinib Dosing Regimen in Patients With Myelofibrosis: An Open-Label Phase 2 Study

A recent phase 2 study found that using a dose-escalation approach with ruxolitinib in patients with intermediate- to high-risk myelofibrosis may decrease the occurrence and severity of associated hematologic adverse events.

 Journal of Hematology & Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.